5-MeO-MBT

5-MeO-MBT, also known as 5-methoxy-N-methyl-N-butyltryptamine, is a serotonin receptor modulator of the tryptamine and 5-methoxytryptamine families related to 5-MeO-DMT.^[1]

The drug was not included nor mentioned in Alexander Shulgin's book TiHKAL (Tryptamines I Have Known and Loved) and its properties and effects in humans are unknown.^[2]

It shows affinity for the serotonin 5-HT_1A, 5-HT_2A, and 5-HT_2C receptors (K_i = 10nM, 721nM, and 252nM, respectively).^[1] The drug is a partial agonist of the serotonin 5-HT_2A receptor (EC₅₀ Tooltip half-maximal effective concentration = 1,318nM; E_max Tooltip maximal efficacy = 38–47%).^[1] Its affinities for the serotonin 5-HT_1A, 5-HT_2A, and 5-HT_2C receptors were similar to those of 5-MeO-DMT, and it showed only 1.8-fold lower activational potency at the serotonin 5-HT_2A receptor, but it had much lower efficacy in activating the receptor in comparison (E_max = 38–47% and 98%, respectively).^[1]

The chemical synthesis of 5-MeO-MBT has been described.^[1] 5-MeO-MBT has several possible positional isomers, including 5-MeO-MiBT, 5-MeO-MsBT, and 5-MeO-MtBT.^[3]

5-MeO-MBT was first described in the scientific literature by Niels Jensen in 2004.^[1]

• Substituted tryptamine
• 5-MeO-DBT

• 5-MeO-MBT - Isomer Design